<sup>18</sup>F-FDG PET/CT对非小细胞肺癌淋巴结分期诊断价值的研究进展

张毓艺; 姚稚明; 张毓艺; 姚稚明

doi:10.3760/cma.j.issn.1673-4114.2016.06.009

[1]

Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66(2):115-132. DOI:10.3322/caac.21338.

[2]

支修益, 石远凯, 于金明.中国原发性肺癌诊疗规范(2015年版)[J].中华肿瘤杂志, 2015, 37(1):67-78. DOI:10.3760/cma.j.issn.0253-3766.2015.01.014.
Zhi XY, Shi YK, Yu JM.Standards for the diagnosis and treatment of primary lung cancer(2015 version) in China[J].Chin J Oncol, 2015, 37(1):67-78. doi: 10.3760/cma.j.issn.0253-3766.2015.01.014

[3]

孙志超, 吴仪仪, 余仲飞, 等.增强CT与PET/CT在诊断肺癌及其淋巴结转移中的价值[J].医学研究杂志, 2014, 43(10):42-45.
Sun ZC, Wu YY, Yu ZF, et al.Evaluation of enhancement CT combined with PET/CT in diagnosis of lung cancer and lymph node[J].J Med Res, 2014, 43(10):42-45.

[4]

吴仪仪, 张建, 左长京, 等.PET/CT与增强CT对肺癌淋巴结诊断及分期的比较[J].临床肺科杂志, 2014, 19(10):1846-1848. DOI:10.3969/j.issn.1009-6663.2014.010.035.
Wu YY, Zhang J, Zuo CJ, et al.Comparison of nodal staging between PET/CT and CECT in patient with lung cancer[J].J Clin Pulmonary Med, 2014, 19(10):1846-1848. doi: 10.3969/j.issn.1009-6663.2014.010.035

[5]

Lee PC, Port JL, Korst RJ, et al.Risk factors for occult mediastinal metastases in clinical stage Ⅰ non-small cell lung cancer[J].Ann Thorac Surg, 2007, 84(1):177-181. DOI:10.1016/j.athoracsur.2007.03.081.

[6]

Higashi K, Ito K, Hiramatsu Y, et al.¹⁸F-FDG uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer:analysis of a multicenter study[J].J Nucl Med, 2005, 46(2):267-273.

[7]

Park HK, Jeon K, Koh WJ, et al.Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT[J].Respirology, 2010, 15(8):1179-1184. DOI:10.1111/j.1440-1843.2010.01793.x.

[8]

Miyasaka Y, Suzuki K, Takamochi K, et al.The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer[J].Eur J Cardiothorac Surg, 2013, 44(1):83-87. DOI:10.1093/ejcts/ezs604.

[9]

Zhao L, He ZY, Zhong XN, et al.¹⁸FDG-PET/CT for detection of mediastinal nodal metastasis in non-small cell lung cancer:A meta-analysis[J].Surg Oncol, 2012, 21(3):230-236. DOI:10.1016/j.suronc.2011.11.001.

[10]

Lv YL, Yuan DM, Wang K, et al.Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer a bivariate systematic review and Meta-Analysis[J].J Thorac Oncol, 2011, 6(8):1350-1358. DOI:10.1097/JTO.0b013e31821d4384.

[11]

Al-Jahdali H, Khan AN, Loutfi S, et al.Guidelines for the role of FDG-PET/CT in lung cancer management[J].J Infect Public Health, 2012, 5 Suppl 1:S35-S40. DOI:10.1016/j.jiph.2012.09.003.

[12]

Wu Y, Li P, Zhang H, et al.Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients[J/OL].Int J Cancer, 2013, 132(2): E37-47[2016-08-08].https://www.ncbi.nlm.nih.gov/pubmed/22890912. DOI: 10.1002/ijc.27779.

[13]

Bryant AS, Cerfolio RJ, Klemm KM, et al.Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer[J].Ann Thorac Surg, 2006, 82(2):417-423. doi: 10.1016/j.athoracsur.2005.12.047

[14]

Tasci E, Tezel C, Orki A, et al.The role of integrated positron emission tomography and computed tomography in the assessment of nodal spread in cases with non-small cell lung cancer[J].Interact Cardiovasc Thorac Surg, 2010, 10(2):200-203. DOI:10.1510/icvts.2009.220392.

[15]

Tournoy KG, Maddens S, Gosselin R, et al.Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant:a prospective study[J].Thorax, 2007, 62(8):696-701. DOI:10.1136/thx.2006.072959.

[16]

Kang WJ, Chung JK, So Y, et al.Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours[J].Eur J Nucl Med Mol Imaging, 2004, 31(2):202-207. DOI:10.1007/s00259-003-1368-x.

[17]

Lee J, Aronchick JM, Alavi A.Accuracy of ¹⁸F fluorodeoxyglucose positron emission tomography for the evaluation malignancy in patients presenting with new lung abnormalities-A retrospective review[J].Chest, 2001, 120(6):1791-1797. DOI:10.1378/chest.120.6.1791.

[18]

段晓蓓, 樊卫, 许泽清, 等.最大标准摄取值诊断非小细胞肺癌纵隔淋巴结转移的最佳界值[J].中国医学影像技术, 2012, 28(5):916-920.
Duan XB, Fan W, Xu ZQ, et al.Optimal threshold in diagnosing mediastinal lymph node metastasis of non-small cell lung cancer with maximum standardized uptake value[J].Chin J Med Imaging Technol, 2012, 28(5):916-920.

[19]

马文超, 徐文贵, 朱湘, 等.¹⁸F-FDG PET/CT SUV_max及CT值双定量分析在肺癌纵隔淋巴结鉴别诊断中的价值[J].中国肿瘤临床, 2011, 38(5):284-287. DOI:10.3969/j.issn.1000-8179.2011.05.011.
Ma WC, Xu WG, Zhu X, et al.Differential diagnosis of mediastinal lymph node metastasis in lung cancer patients using ¹⁸F-FDG PET/CT with double quantitative SUV_max and CT value[J].Chin J Clin Oncol, 2011, 38(5):284-287. doi: 10.3969/j.issn.1000-8179.2011.05.011

[20]

叶鹏飞, 韩星敏, 谢新立, 等.纵隔淋巴结与原发灶最大标准摄取值比值对非小细胞肺癌纵隔淋巴结转移的诊断价值[J].中国医学影像技术, 2014, 30(12):1839-1843.
Ye PF, Han XM, Xie XL, et al.Maximum standardized uptake value ratio of mediastinal lymph node to primary tumor in diagnosis of mediastinal lymph node metastasis in patients with non-small cell lung cancer[J].Chin J Med Imaging Technol, 2014, 30(12):1839-1843.

[21]

Koksal D, Demirag F, Bayiz H, et al.The correlation of SUV_max with pathological characteristics of primary tumor and the value of Tumor/Lymph node SUV_max ratio for predicting metastasis to lymph nodes in resected NSCLC patients[J/OL].J CardiothoracSurg, 2013, 8: 63[2016-08-08].https://www.ncbi.nlm.nih.gov/pubmed/?term=23557204. DOI: 10.1186/1749-8090-8-63.

[22]

Honguero Martínez AF, García Jiménez MD, García Vicente A, et al.Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in ¹⁸F-FDG PET-CT scan[J].Rev Esp Med Nucl Imagen Mol, 2016, 35(3):159-164. DOI:10.1016/j.remn.2015.08.004.

[23]

Kuo WH, Wu YC, Wu CY, et al.Node/aorta and node/liver SUV ratios from ¹⁸F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma[J].Acad Radiol, 2012, 19(6):685-692. DOI:10.1016/j.acra.2012.02.013.

[24]

Hu M, Han A, Xing L, et al.Value of dual-time-point FDG PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity[J].Clin Nucl Med, 2011, 36(6):429-433. DOI:10.1097/RLU.0b013e3182173810.

[25]

Kim DW, Kim WH, Kim CG.Dual-time-point FDG PET/CT:Is It Useful for Lymph Node Staging in Patients with Non-Small-Cell Lung Cancer?[J].Nucl Med Mol Imaging, 2012, 46(3):196-200. DOI:10.1007/s13139-012-0141-0.

[26]

Kasai T, Motoori K, Horikoshi T, et al.Dual-time point scanning of integrated FDG PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT[J].Eur J Radiol, 2010, 75(2):143-146. DOI:10.1016/j.ejrad.2009.04.044..

[27]

Wu LM, Xu JR, Gu HY, et al.Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer:which is better?[J].J Surg Res, 2012, 178(1):304-314. DOI:10.1016/j.jss.2012.03.074.

[28]

Schaarschmidt BM, Buchbender C, Nensa F, et al.Correlation of the apparent diffusion coefficient(ADC) with the standardized uptake value(SUV) in lymph node metastases of non-small cell lung cancer(NSCLC) patients using hybrid ¹⁸F-FDG PET/MRI[J/OL].PLoS One, 2015, 10(1): e0116277[2016-08-08].https://www.ncbi.nlm.nih.gov/pubmed/?term=25793286. DOI: 10.1371/journal.pone.0120606.

[29]

Huellner MW, de Galiza Barbosa F, Husmann L, et al.TNM Staging of Non-Small Cell Lung Cancer:Comparison of PET/MR and PET/CT[J].J Nucl Med, 2016, 57(1):21-26. DOI:10.2967/jnumed.115.162040.

[30]

Kohan AA, Kolthammer JA, Vercher-Conejero JL, et al.N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm:Initial experience[J].EurRadiol, 2013, 23(11):3161-3169. DOI:10.1007/s00330-013-2914-y.

[31]

Schwenzer NF, Schraml C, Müller M, et al.Pulmonary lesion assessment:comparison of whole-body hybrid MR/PET and PET/CT imaging——pilot study[J].Radiology, 2012, 264(2):551-558. DOI:10.1148/radiol.12111942.

[32]

Herbrik M, Treffert J, Geiger B, et al.Diagnostic accuracy of virtual ¹⁸F-FDG PET/CT bronchoscopy for the detection of lymph node metastases in non-small cell lung cancer patients[J].J Nucl Med, 2011, 52(10):1520-1525. DOI:10.2967/jnumed.111.092593.

[33]

Buchbender C, Herbrik M, Treffert JA, et al.Virtual ¹⁸F-FDG PET/CT bronchoscopy for lymph node staging in non-small-cell lung cancer patients:present and future applications[J].Expert Rev Med Devices, 2012, 9(3):241-247. DOI:10.1586/ERD.12.9.

[34]

Lasnon C, Hicks RJ, Beauregard J, et al.Impact of point spread function Reconstruction on thoracic lymph node staging with ¹⁸F-FDG PET/CT in Non-Small cell lung cancer[J].Clin Nucl Med, 2012, 37(10):971-976. DOI:10.1097/RLU.0b013e318251e3d1.